Internal Medicine | Page 145 of 487 | Links Medicus Content Curation & Alerts in Medicine

New UK Guidance: Self-isolation for those with COVID-19 can end after 5 full days following 2 negative rapid lateral flow tests – “The default self-isolation period continues to be 10 days, and you may only leave self-isolation early if you have taken 2 rapid lateral flow tests and do not have a temperature in line with guidance”.

14 Jan, 2022 | 08:48h | UTC

Self-isolation for those with COVID-19 can end after 5 full days following 2 negative LFD tests – Department of Health and Social Care

Commentary on Twitter (thread – click for more)

Self-isolation period for people infected with COVID in England will be reduced to 5 days from Monday 17 Jan. But it's conditional: 2 NEGATIVE tests on days 5 & 6, & no symptoms, & not in certain high risk situations e.g. working with vulnerable people
1/https://t.co/HLxlIbpbkR

— Andrew Lee is heading to @andrewleedr.bsky.social (@andrewleedr) January 13, 2022

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

14 Jan, 2022 | 08:37h | UTC

Fluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Commentary on Twitter

Thinking of prescribing fluvoxamine for covid 19? Ontario has a nice infographichttps://t.co/MKT8PqlJpM

— Todd C. Lee (@DrToddLee) January 12, 2022

Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of Covid-19.

14 Jan, 2022 | 08:39h | UTC

Perioperative Cardiovascular Considerations Prior to Elective Noncardiac Surgery in Patients With a History of COVID-19 – JAMA Surgery

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

BJS commission on surgery and perioperative care post-COVID-19.

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

Cohort Study: Patients who achieved weight loss through bariatric surgery may have lower risk for severe Covid-19 compared to patients who did not have surgical intervention for their obesity.

14 Jan, 2022 | 08:32h | UTC

Association of Weight Loss Achieved Through Metabolic Surgery With Risk and Severity of COVID-19 Infection – JAMA Surgery

Commentaries:

Is COVID-19 the Newest Comorbidity of Obesity Mitigated by Bariatric Surgery? – JAMA Surgery

Can weight loss help protect against Covid-19? – CNN

Perspective: Omicron is forcing us to rethink mild COVID.

14 Jan, 2022 | 08:30h | UTC

Omicron Is Forcing Us to Rethink Mild COVID – The Atlantic

RCT: Colchicine did not significantly reduce the need for intubation or 28-day mortality in patients hospitalized with Covid-19.

14 Jan, 2022 | 08:35h | UTC

Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial – JAMA Network Open

M-A: Colchicine doesn’t lessen COVID-19 severity or stave off risk of death.

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

Commentary on Twitter

This randomized clinical trial found that colchicine did not significantly reduce mechanical ventilation or mortality in patients hospitalized with #COVID19 pneumonia. @DLBhattMD https://t.co/2nU5Ks74uF pic.twitter.com/VvHhTFnBhV

— JAMA Network Open (@JAMANetworkOpen) December 29, 2021

AAN Position Statement: Consent Issues in the Management of Acute Ischemic Stroke.

14 Jan, 2022 | 08:24h | UTC

Consent Issues in the Management of Acute Ischemic Stroke: AAN Position Statement – Neurology

News Release: Who gives consent for treatment when a person with stroke cannot? – American Academy of Neurology

Systematic Review: Restrictive transfusion thresholds can safely decrease transfusions by 41% across a broad range of clinical contexts.

14 Jan, 2022 | 08:18h | UTC

Transfusion thresholds for guiding red blood cell transfusion – Cochrane Library

Summary: Is it safe to use lower blood counts (haemoglobin levels) as a trigger for blood transfusion in order to give fewer blood transfusions? – Cochrane Library

RCT: Among patients with acute MI and anemia, a restrictive transfusion strategy resulted in a noninferior rate of major cardiovascular events compared to a liberal transfusion strategy

Randomized trial: Liberal vs. restrictive transfusion thresholds in extremely low-birth-weight infants

Meta-Analysis: Effects of Restrictive vs. Liberal Transfusion Strategies on Longer-term Outcomes After Cardiac Surgery

Randomized Trial: In Patients Undergoing Cardiac Surgery, A Restrictive Transfusion Approach Does Not Increase the Risk of Acute Kidney Injury

Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials – Critical Care

Research: Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery

Transfusion Requirements After Cardiac Surgery: The TRACS Randomized Controlled Trial – JAMA

Commentary on Twitter

https://twitter.com/cochraneINJ/status/1473667822542888964

Feature | The top ten: key trials in 2021 making a difference in cardiology clinical practice.

14 Jan, 2022 | 08:22h | UTC

Feature | The Top Ten: Key Trials in 2021 Making a Difference in Clinical Practice – American College of Cardiology

Review: Migraine.

14 Jan, 2022 | 08:16h | UTC

Migraine – Nature Reviews Disease Primers (if the link is paywalled, try this one)

Infographic: Migraine (if the link is paywalled, try this one)

Systematic Review: In patients with intermittent claudication, Propionyl‐L‐carnitine may improve walking distance when compared to placebo (moderate overall certainty of evidence).

14 Jan, 2022 | 08:02h | UTC

Propionyl‐L‐carnitine for intermittent claudication – Cochrane Library

Summary: Propionyl-L-carnitine for intermittent claudication – Cochrane Library

RCT: In patients with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis) treated with Infliximab, a proactive therapeutic drug monitoring protocol was more likely to lead to sustained disease control.

14 Jan, 2022 | 07:57h | UTC

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary on Twitter

Study found proactive therapeutic drug monitoring (TDM) compared with treatment without TDM during maintenance infliximab therapy was more likely to lead to sustained disease control over 52 weeks for patients with immune-mediated inflammatory diseases https://t.co/yfJjyADaOT pic.twitter.com/JtOfQxFFDS

— JAMA (@JAMA_current) December 21, 2021

Observational study in adolescents showed the Pfizer-BioNTech vaccine had an overall effectiveness of 94% against hospitalization and 98% against critical Covid-19.

13 Jan, 2022 | 09:00h | UTC

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents – New England Journal of Medicine

Editorial: Sparing of Severe Covid-19 in Vaccinated Adolescents – New England Journal of Medicine

Study shows COVID-19 vaccines offer lasting protection against hospitalization and death.

13 Jan, 2022 | 09:01h | UTC

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines – New England Journal of Medicine

News Release: Study shows COVID-19 vaccines offer lasting protection – University of North Carolina at Chapel Hill

An observational study in South Africa estimates the Pfizer vaccine had an effectiveness of 70% against hospitalization for Covid-19 caused by the omicron variant.

13 Jan, 2022 | 08:56h | UTC

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa – New England Journal of Medicine

Commentary: BNT162b2 still effective, but less so, against Omicron – HealthDay

RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19.

13 Jan, 2022 | 08:54h | UTC

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients – New England Journal of Medicine

Editorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?

Commentary: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress

Commentary on Twitter

Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. #COVID19 #IDTwitter https://t.co/YFflw5nBxB pic.twitter.com/4NCD9AcnYH

— NEJM (@NEJM) December 22, 2021

Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized.

13 Jan, 2022 | 08:48h | UTC

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial – The Lancet Infectious Diseases

Invited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19

‘Killer’ immune cells still recognize Omicron variant.

13 Jan, 2022 | 08:51h | UTC

‘Killer’ immune cells still recognize Omicron variant – Nature

A clinical case definition of post-COVID-19 condition by a Delphi consensus.

13 Jan, 2022 | 08:45h | UTC

A clinical case definition of post-COVID-19 condition by a Delphi consensus – The Lancet Infectious Diseases

Commentary on Twitter

New Review: A clinical case definition of post-#COVID19 condition by a Delphi consensus https://t.co/AoWBgCeMq5 pic.twitter.com/kAW1YY6kgr

— The Lancet Infectious Diseases (@TheLancetInfDis) December 22, 2021